# Carbapenem Resistance in Clinical Enterobacteriaceae Isolates

**Dr Jeanette TEO**  
Scientific Officer  
Department of Laboratory Medicine  
National University Hospital

## Abstract

Carbapenems (imipenem, ertapenem, meropenem, doripenem) are the antimicrobial drugs of last resort for the treatment of infections caused by extended-spectrum β-lactamases (ESBLs) producing bacteria. These agents are crucial for preventing and treating life-threatening nosocomial infections. The first carbapenemase producer in Enterobacteriaceae (NmcA) was identified in 1993, since then carbapenem-resistant Enterobacteriaceae have been reported in ever increasing numbers worldwide. A large variety of carbapenemases has been identified in Enterobacteriaceae belonging to 3 classes of β-lactamases: the Ambler class A, B, and D β-lactamases. In this presentation, we describe the molecular characterization of carbapenemase producing clinical Enterobacteriaceae isolates obtained through local surveillance efforts.

## Selected Publications

1. Teo Jeanette, Michelle Balm, Grace Ngan, Roland Jureen, and Raymond Lin Molecular characterization of OXA-181 producing Enterobacteriaceae in Singapore [In preparation]

